The “rights” of precision drug development for Alzheimer’s disease
Abstract There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in mult...
Main Authors: | Jeffrey Cummings, Howard H. Feldman, Philip Scheltens |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-019-0529-5 |
Similar Items
-
Use of Biomarkers in Ongoing Research Protocols on Alzheimer’s Disease
by: Marco Canevelli, et al.
Published: (2020-07-01) -
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
by: Gayatri Devi, et al.
Published: (2018-12-01) -
Drug candidates in clinical trials for Alzheimer’s disease
by: Shih-Ya Hung, et al.
Published: (2017-07-01) -
Repurposed agents in the Alzheimer’s disease drug development pipeline
by: Justin Bauzon, et al.
Published: (2020-08-01) -
Anticancer drugs repurposed for Alzheimer’s disease: a systematic review
by: Antonio Ancidoni, et al.
Published: (2021-05-01)